Top

News & Events

Archive: 2018

News Archive

European Mediscience Awards 2018

14 June 2018

European Mediscience Awards 2018

London, UK

Read more »

BioWednesday

13 June 2018

BioWednesday

London, UK

Read more »

Women in Biotech Networking Evening

8 March 2018

Women in Biotech Networking Evening

London, UK

Read more »

UK IPO Bootcamp

7 February 2018

UK IPO Bootcamp

London, UK

Read more »

Biotech and Money / Medtech and Money World Congress

5-6 February 2018

Biotech and Money / Medtech and Money World Congress

London, UK

Read more »

Biotech and the City

25 January 2018

Biotech and the City

London, UK

Read more »

BIA Gala Dinner 2018

25 January 2018

BIA Gala Dinner 2018

London, UK

Read more »

Seventure Joins $35m Series B Round in Digital Nutrition Platform Zipongo

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces that it has joined a Series B funding round into Zipongo, investing $9m.

Read more »

Abcam Signs Exclusive License Agreement with Roche

Cambridge, UK – Abcam plc ("Abcam"), a global leader in the supply of life science research tools, is pleased to announce that it has entered into a definitive license agreement with Roche. Under the terms of the agreement Abcam will obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation (“Spring”) in the research use only (RUO) field of use, comprising a total of approximately 760 unique products (the “Spring Portfolio”). Roche, which acquired Spring in 2007, will retain the antibody development capabilities and rights pertaining to the Spring Portfolio for internal research, companion diagnostic and IVD uses.

Read more »

Biotech and Money presents Biotech and Money/Medtech and Money World Congress on 5-6 February 2018

London, UK On 5-6 February, over 500 leading lights, emerging stars, C-suite executives, impactful investors and powerful stakeholders will attend the 4th annual Biotech and Money/Medtech and Money World Congress. The congress is a high-calibre, senior executive, two-day conference and partnering event providing the education, strategies, solutions and contacts that life science companies need to enable more effective investment, business planning, and partnering within their businesses.

Read more »

OBN BioThirstday

18 January 2018

OBN BioThirstday

London, UK

Read more »

FuturaGene’s Exclusive License For RNAi Technology In Eucalyptus Enhanced By Grant Of Patent In Brazil

Canberra, Australia and Sao Paulo, Brazil – FuturaGene, a wholly owned subsidiary of Suzano Pulp and Paper, and Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO), are pleased to announce that a patent has been issued in Brazil to CSIRO, which covers the downregulation of the expression of plant target genes or other target genes, including genes of insect pests and disease agents. In 2014, FuturaGene entered into an exclusive license agreement with CSIRO for the use of RNAi technology in eucalyptus in Brazil. Under the license, FuturaGene has the right to sublicense the technology and has non-exclusive rights to the technology in eucalyptus outside of Brazil.  FuturaGene has been utilizing the technology to develop varieties of eucalyptus, which are resistant to pests and diseases and for modifying wood properties.

Read more »

Immatics Appoints Thomas Ulmer as Chief Financial Officer

Tuebingen, Germany and Houston, Texas – Immatics, a leading company in the field of cancer immunotherapy, today announced the appointment of Thomas Ulmer as Chief Financial Officer (CFO), effective April 1, 2018.

Read more »

Clinigen Group plc: HY trading update: good H1 performance with profits up over 10%

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, today provides a trading update for the six months ended 31 December 2017.

Read more »

e-Therapeutics to collaborate with Intellegens and Biorelate to enhance and extend its AI technology capabilities

Oxford, UK - e-Therapeutics, a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, today announces agreements with Intellegens and Biorelate. Both companies have artificial intelligence (AI) tools which, after pilot studies, have been proven to enhance ETX’s existing computational NDD technology. No financial details were disclosed.

Read more »

AusIndustry Awards Recce Support for AU$5.6m of Technically Advanced Overseas Drug Development

SYDNEY Australia – Recce Pharmaceuticals Ltd (ASX: RCE), developing a new class of synthetic antibiotics, today announced that it has been awarded an Advanced Finding upon AU$5.6 million of overseas drug development from AusIndustry, a division of the Australian Government’s Department of Industry, Innovation and Science.

Read more »

Seventure Partners Life Sciences Investing Update - H2 2017

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces its corporate update for July – December 2017.

Read more »

One Nucleus Pub Social

10 January 2018

One Nucleus Pub Social

London, UK

Read more »

The UK BIA has launched a Best Practice Guide for Communicating R&D Progress to Investors and the Public

We welcome the launch of a new BioIndustry Association (BIA) guide to help bioscience companies communicate their R&D clearly and effectively to investors and the public.

Drawing on our decades or experience of advising public and private biotech companies in the UK and globally, Instinctif Partners supported the development of the guide, which can be downloaded HERE.

Read our INSIGHT on the importance of best practice communications in the biotech sector HERE.

Read more »

Abzena takes on new facilities in Cambridge, UK and San Diego

Cambridge, UK – Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, provides an update on its UK and US facilities.

Read more »

Instinctif Partners Welcomes the Publication of the new BIA Best Practice Guide for Communicating R&D Progress to Investors and the Public

London, UK - The life sciences team at International business communications consultancy Instinctif Partners welcomes the launch of a new guide to help bioscience companies communicate their R&D clearly and effectively to investors and the public.

Read more »

Clinigen extends agreement with Eisai to supply Halaven®, Fycompa® and Lenvima® into 10 African countries

Clinigen Group plc (AIM: CLIN, ‘Clinigen’) - Clinigen Group plc, the global pharmaceutical and services company, has extended its exclusive agreement with Eisai Europe Ltd to obtain the marketing authorisation and subsequently launch Halaven® (eribulin), Fycompa® (perampanel) and Lenvima® (lenvatinib) into 10 African countries.

Read more »